Haohai Biotechnology (06826) announced its interim results, with profit attributable to common equity holders of approximately 2.11 billion yuan, a year-on-year decrease of about 10.29%.

The Zhitong Financial APP news, Haohai Biotechnology (06826) announced its mid-term performance in 2025, with operating income of approximately RMB 1.293 billion, a decrease of about 7.48% year-on-year; the net profit attributable to common equity holders is about RMB 211 million, a decrease of about 10.29% from the same period in 2024. Basic earnings per share is 0.91 yuan, and the mid-term dividend is RMB 0.40 per share.